Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 13/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.93 |
| ▸ | JUN | P05412 | 4/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4395645 | 0.96 | ADORA3 (1.00) | ADORA3ADORA1JUNALDH1A1NFKB1 | |
| SCHEMBL4397163 | 0.91 | ADORA3 (0.84) | ADORA3ADORA1JUNNFKB1NFKB2 | |
| SCHEMBL4401529 | 0.91 | ADORA3 (0.84) | ADORA3ADORA1JUNALDH1A1NFKB1 | |
| SCHEMBL4398544 | 0.91 | ADORA3 (1.00) | ADORA3ADORA1JUNALDH1A1NFKB1 | |
| SCHEMBL4401440 | 0.91 | ADORA3 (1.00) | ADORA3ADORA1JUNNFKB1NFKB2 | |
| SCHEMBL4395373 | 0.89 | ADORA3 (0.86) | ADORA3ADORA1JUNALDH1A1NFKB1 | |
| SCHEMBL4399816 | 0.89 | ADORA3 (0.96) | ADORA3ADORA1JUNALDH1A1NFKB1 | |
| SCHEMBL4401374 | 0.89 | JUN (0.86) | ADORA3ADORA1JUNALDH1A1NFKB1 | |
| SCHEMBL4402526 | 0.88 | ADORA3 (1.00) | ADORA3ADORA1JUNNFKB1NFKB2 | |
| SCHEMBL4401382 | 0.87 | ADORA3 (0.93) | ADORA3ADORA1JUNALDH1A1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8829014-B2 | Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2014-09-09 | — | — | US | disclosed |
| EP-2007393-B1 | THIAZOLE AND THIOPHENE ANALOGUES, AND THEIR USE IN TREATING AUTOIMMUNE DISEASES AND CANCERS | UNIV LOUISIANA STATE (US) | 2013-08-21 | — | — | EP | disclosed |
| US-20120283268-A1 | Thiazole and Thiophene Analogues, and Their Use in Treating Autoimmune Diseases and Cancers | GIORDANO ANTHONY (US) | 2012-11-08 | — | — | US | disclosed |
| US-8217037-B2 | Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2012-07-10 | — | — | US | disclosed |
| US-20090306073-A1 | Thiazole and Thiophene Analogues, and Their Use in Treating Autoimmune Diseases and Cancers | B.V. PATEL PHARMACEUTICAL EDUCATION & RESEARCH DEVELOPMENT (PERD) CENTRE (IN) | 2009-12-10 | — | — | US | disclosed |
| EP-2007393-A2 | THIAZOLE AND THIOPHENE ANALOGUES, AND THEIR USE IN TREATING AUTOIMMUNE DISEASES AND CANCERS | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College (US) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007118149-A2 | THIAZOLE AND THIOPHENE ANALOGUES, AND THEIR USE IN TREATING AUTOIMMUNE DISEASES AND CANCERS | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL LOLLEGE (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306073-A1 | Thiazole and Thiophene Analogues, and Their Use in Treating Autoimmune Diseases and Cancers | TPMT, TST, SSB | ADORA3 3140/4885ADORA1 3601/4885JUN 2228/4885 |
| US-20120283268-A1 | Thiazole and Thiophene Analogues, and Their Use in Treating Autoimmune Diseases and Cancers | TPMT, TST, SSB | ADORA3 3140/4885ADORA1 3601/4885JUN 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.